Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

XLV vs XBI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XLV Captures Overall Composite Edge (48.1 HOLD vs 52.9 HOLD), While XBI Leads 1–0 on Growth & Valuation Pillars

XLV Overall Winner 6-Pillar Tally: XLV 0 – 1 XBI (5 Tie) Matrix Metrics: XLV 2 – 1 XBI

As of Nov 20, 2026, Health Care Select Sector SPDR Fund (XLV) captures the overall head-to-head institutional edge over SPDR S&P Biotech ETF (XBI) on higher Unified Composite conviction (48.1/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 2–1 (led by composite factor balance), while XBI wins 1–0 across the 6-pillar growth and valuation breakdown. XLV trades at $177.24 (N/M Forward P/E, N/A operating margin) versus XBI at $140.18 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While XBI currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. XLV 48.1/100 HOLD), XLV captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Technical & Structure Timing Caution: XLV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 40.7); meanwhile XBI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XLV vs XBI
XLV NYSE Arca Head-to-Head Winner
Health Care Select Sector SPDR Fund
Institutional Equity
$177.24
-0.12% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.26β · 22% Vol
Unified Composite Score
48.1 / 100 HOLD
Tech 42.0 Fund 46.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 40.7 · SMA20: $184.35 · SMA50: $176.50
XBI NYSE Arca
SPDR S&P Biotech ETF
Institutional Equity
$140.18
-2.73% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.17β · 38% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 23.0 Fund 51.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.9%), weak momentum, RSI 35
RSI-14: 35.5 · SMA20: $151.69 · SMA50: $152.71

6-Pillar Scorecard Institutional Category Breakdown (XLV 0 – 1 XBI)

Columns: Metric · XLV · XBI
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XBI
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 13.0% (1st %ile) 58.6% (17th %ile)
Put/Call OI Skew N/A 1.27x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XLV (2) vs XBI (1)
Institutional Metric XLV XBI Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
70% ($142–$192) 47% ($113–$170) Stronger Trend XLV
Beta / 30D Volatility
Risk Regime
0.26β · 22% Vol 1.17β · 38% Vol Lower Realized Risk XLV
Unified Institutional Score
Composite Signal
48.1 / 100 (HOLD) 52.9 / 100 (HOLD) Higher Composite XBI
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XLV +5.32 pp
XLV: -2.24% · XBI: -7.56%
3M Horizon XLV +16.06 pp
XLV: +1.45% · XBI: -14.61%
6M Horizon XLV +11.78 pp
XLV: +18.25% · XBI: +6.47%
1Y Horizon XBI +6.08 pp
XLV: +16.35% · XBI: +22.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XLV vs XBI. Trailing 12-month operating profitability (XLV N/A vs XBI N/A) and valuation multiples (XLV N/M vs XBI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XLV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
XBI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XLV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 13.0%
IV Percentile 1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XLV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XBI CONSOLIDATION
66d in phase · OBV DISTRIBUTION
Current IV 58.6%
IV Percentile 17th %ile
Put/Call OI Skew 1.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact XBI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $145.88 · IV 33.9%

XBI Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($14,588)

Compare $14,588 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 33.9% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $145 / $155 Bull Call Spread

Buy 1x $145C · Sell 1x $155C · 32d

Net Entry $478 Debit
T+5d @ +5% Move +$174 (+36%)
Max Risk / Buffer $478 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $140 / $130 Bull Put Spread

Sell 1x $140P · Buy 1x $130P · 32d

Net Entry $232 Credit
Max Credit / Yield +$232 (+30.2% RoM)
Max Risk / Buffer -5.6% Cushion ($768 Mgn)
5d Edge & Liquidity 69% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Asymmetric 1x1x1 ($150C + $146/$135P)

+1x 11d $146P · -1x 38d $135P · +1x 32d $150C

Net Entry $510 Debit
T+5d @ +5% Move +$213 (+8.4% RoM)
Max Risk / Buffer -7.5% Put Cushion ($2,540 Mgn)
5d Edge & Liquidity Hedged @ -6% (+$90) · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XLV Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XBI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XLV vs XBI Key Questions & Quantitative Answers

As of Nov 20, 2026, Health Care Select Sector SPDR Fund (XLV) captures the overall head-to-head institutional edge over SPDR S&P Biotech ETF (XBI) on higher Unified Composite conviction (48.1/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 2–1 (led by composite factor balance), while XBI wins 1–0 across the 6-pillar growth and valuation breakdown. XLV trades at $177.24 (N/M Forward P/E, N/A operating margin) versus XBI at $140.18 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While XBI currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. XLV 48.1/100 HOLD), XLV captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: XLV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 40.7); meanwhile XBI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XLV and XBI split Growth & Scale metrics: XLV posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with XBI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, XLV generates N/A in USD-normalized revenue versus N/A for XBI. In operating R&D and SG&A reinvestment, XLV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XBI.

XLV and XBI trade at balanced relative valuation multiples. XLV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas XBI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XLV (N/A ROE) versus XBI (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, XLV carries 13.0% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.26β · 22% Vol realized risk). By comparison, XBI carries 58.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.17β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.